Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and E
Jacobio Pharma has reported the results of its pivotal Chinese study of KRAS G12C inhibitor glecirasib, with a safety profile that could differentiate it from other drugs
Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world's second-
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
